These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 2475373)
1. Biological approaches to cancer therapy. Thomas H; Sikora K J Int Med Res; 1989; 17(3):191-204. PubMed ID: 2475373 [TBL] [Abstract][Full Text] [Related]
2. New therapeutic modalities for cancer. Thomas H; Sikora K Acta Oncol; 1991; 30(1):107-20. PubMed ID: 1706927 [TBL] [Abstract][Full Text] [Related]
3. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428 [TBL] [Abstract][Full Text] [Related]
5. [Monoclonal antibodies and mediators--immunologic tumor therapy]. Baron D Naturwissenschaften; 1990 Sep; 77(9):405-11. PubMed ID: 1701222 [TBL] [Abstract][Full Text] [Related]
6. Cytokines in tumour therapy. Hill AD; Redmond HP; Croke DT; Grace PA; Bouchier-Hayes D Br J Surg; 1992 Oct; 79(10):990-7. PubMed ID: 1384923 [TBL] [Abstract][Full Text] [Related]
7. The role of T lymphocytes in the immunotherapy of tumours. Brondz BD; Balashov KE Biomed Sci; 1991; 2(5):441-9. PubMed ID: 1840832 [TBL] [Abstract][Full Text] [Related]
8. Biologics as cancer treatment modalities. Smalley RV Wis Med J; 1987 Nov; 86(11):19-21. PubMed ID: 2447705 [No Abstract] [Full Text] [Related]
9. Immunological approaches to the treatment of malignant disease. Guillou PJ J R Coll Surg Edinb; 1988 Feb; 33(1):2-8. PubMed ID: 2458468 [No Abstract] [Full Text] [Related]
10. Biological response modifiers. Interferons, interleukins, and transfer factor. Kirkpatrick CH Ann Allergy; 1989 Mar; 62(3):170-6. PubMed ID: 2466425 [TBL] [Abstract][Full Text] [Related]
14. New antineoplastic therapies and inherent risks: monoclonal antibodies, biologic response modifiers and interleukin-2. Dillman JB J Intraven Nurs; 1989; 12(2):103-13. PubMed ID: 2475596 [TBL] [Abstract][Full Text] [Related]
15. The interferons. Toy JL Clin Exp Immunol; 1983 Oct; 54(1):1-13. PubMed ID: 6193915 [TBL] [Abstract][Full Text] [Related]
16. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC). Oldham RK; Lewko WM; Good RW; Sharp E In Vivo; 1994; 8(5):653-63. PubMed ID: 7537108 [TBL] [Abstract][Full Text] [Related]
18. The role of biotherapies (interleukins, interferons and erythropoietin) in multiple myeloma. Avvisati G; Petrucci MT; Mandelli F Baillieres Clin Haematol; 1995 Dec; 8(4):815-29. PubMed ID: 8845574 [TBL] [Abstract][Full Text] [Related]
19. [The value of interferons, interleukin-2 and tumor necrosis factor in the therapy of renal cell cancer]. Wirth M Urologe A; 1991 Mar; 30(2):77-80. PubMed ID: 1711729 [TBL] [Abstract][Full Text] [Related]
20. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies]. Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F Strahlenther Onkol; 2004 Jun; 180(6):331-9. PubMed ID: 15175867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]